Reduced microperfusion due to portal vein thrombosis: Impact on the outcome of percutaneous thermal tumor ablation

Issue title: Selected papers of the 36th Conference of the German Society for Clinical Microcirculation and Hemorheology, 5–8. June, 2017, Greifswald, Germany

Guest editors: M. Jünger, A. Krüger-Genge and F. Jung

Article type: Research Article

Authors: Pregler, B.^{; *} | Beyer, L.P. | Wiesinger, I. | Haimerl, M. | Stroszczynski, C. | Jung, E.M. | Wiggermann, P.

Affiliations: Department of Radiology, University Hospital Regensburg, Regensburg, Germany

Correspondence: [*] Corresponding author: Benedikt Pregler, Department of Radiology, University Hospital Regensburg, 93053 Regensburg, Germany. Tel.: +49 941 944 7401; E-mail: benedikt.pregler@ukr.de.

Abstract: PURPOSE:To determine the influence of pre-interventionally existing portal vein thrombosis on the ablation success of percutaneous tumor ablation of HCC. MATERIALS AND METHODS:15 patients with HCC and pre-existing portal vein thrombosis underwent thermal tumor ablation. We retrospectively analyzed the pre- and post-interventionally performed CT and MRI scans in terms of technical success as well as the complication rate. The portal vein thrombosis was classified into segmental, lobar and central thrombus. RESULTS:In 13/15 cases (87%) complete ablation with no evidence of residual tumor tissue was seen 6 weeks after the procedure in contrast-enhanced MRI scans and contrast-enhanced ultrasound (CEUS). No major and 2 minor complications were observed after the ablation procedure. CONCLUSION:Reduced perfusion due to pre-interventionally existing portal vein thrombosis has no significant impact on the ablation success or the complication rate.

Keywords: HCC, portal vein thrombosis, ablation, RFA, MWA

DOI: 10.3233/CH-179218

Journal: Clinical Hemorheology and Microcirculation, vol. 67, no. 3-4, pp. 383-388, 2017